Ignite Creation Date:
2025-12-24 @ 3:42 PM
Ignite Modification Date:
2025-12-26 @ 7:17 AM
Study NCT ID:
NCT03408392
Status:
COMPLETED
Last Update Posted:
2020-02-25
First Post:
2018-01-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-02-06
Start Date Type:
ACTUAL
Primary Completion Date:
2018-03-13
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-03-13
Completion Date Type:
ACTUAL
First Submit Date:
2018-01-17
First Submit QC Date:
None
Study First Post Date:
2018-01-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2018-12-11
Results First Submit QC Date:
None
Results First Post Date:
2019-03-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-02-17
Last Update Post Date:
2020-02-25
Last Update Post Date Type:
ACTUAL